Oxurion - Piece of Belgian biotech history coming to an end
*This morning, OXUR announced topline results of part B of the Ph2 KALAHARI study with THR-149 for diabetic macular edema. Data indicated no improvement in vision and, as a result thereof, OXUR will file for bankruptcy. The company added that “while there was a very strong scientific rationale for using THR-149, this was a very hard patient population to treat”. Full dataset will be shared later.*Considering the risk profile (THR-149 sole remaining asset in development) of the company, the low cash position, and highly dilute nature of the financing agreement the company has/has in place with Atlas/Negma, most institutional investorsThromboGenics is an integrated biopharmaceutical company based in Belgium. Co. is focused on developing and commercializing ophthalmic medicines. Co.'s primary product JETREA® (ocriplasmin), has been approved by the U.S. FDA for the treatment of symptomatic Vitreomacular Adhesion (VMA). In Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Co. is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.